Amgen Inc. (AMGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN)

AMGN 317.77

+0.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (1293)	9/19/2006 5:49:55 PM
From: DewDiligence_on_SI	Read Replies (1) of 1906

Amgen Announces License Agreement with Yeda Research and Development Company Ltd. [My guess is AMGN is paying Yeda less than 1% of Panitumumab sales for this non-exclusive license.] biz.yahoo.com >> Tuesday September 19, 5:17 pm ET License Agreement Accords Amgen Freedom to Operate Under '866 Patent THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 19, 2006--Amgen (NASDAQ: AMGN ), the world's largest biotechnology company, today announced that it has entered into an agreement with Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science. Under the terms of the agreement Amgen obtained a license under Yeda's rights in U.S. Patent No. 6,217,866 (the "'866 Patent"). Yesterday, Yeda was awarded sole ownership of the '866 Patent in an opinion and order issued by the U.S. District Court for the Southern District of New York. <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next